Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole

J. D. Sobel, P. S. Kapernick, M. Zervos, B. D. Reed, Thomas Hooton, D. Soper, P. Nyirjesy, M. W. Heine, J. Willems, H. Panzer, H. Wittes

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

OBJECTIVE: An attempt was made to validate recent recommendations that women with complicated Candida vaginitis (severe or recurrent, non-albicans Candida spp or abnormal host) require longer-duration antifungal therapy to achieve clinical cure and mycologic eradication. STUDY DESIGN: A prospective, multicenter, randomized, double-blind study was performed comparing a single dose of 150 mg of fluconazole with 2 sequential 150-mg doses of fluconazole given 3 days apart. RESULTS: Five hundred fifty-six women with severe or recurrent Candida vaginitis were enrolled, and 398 had at least one postbaseline evaluation (intent to treat) and of these 309 were fully evaluable (efficacy-valid). At baseline, 92% of vaginal isolates were Candida albicans. The 2-dose fluconazole regimen achieved significantly higher clinical cure rates in women with severe vaginitis when evaluated on day 14 (P = .015) and higher clinical and mycologic responses persisted at day 35. Women with recurrent but not severe vaginitis did not benefit clinically short term by the additional fluconazole dose. Multivariate logistic regression analysis showed that being infected with non-albicans Candida predicted significantly reduced clinical and mycologic response regardless of duration of therapy. Fluconazole therapy was well tolerated and free of serious adverse effects. CONCLUSION: Treatment of Candida vaginitis requires individualization, and women with severe Candida vaginitis achieve superior clinical and mycologic eradication with a 2-dose fluconazole regimen.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume185
Issue number2
DOIs
StatePublished - Aug 31 2001
Externally publishedYes

Fingerprint

Vaginitis
Fluconazole
Candida
Therapeutics
Candida albicans
Double-Blind Method
Logistic Models
Regression Analysis

Keywords

  • Candida
  • Complicated
  • Fluconazole
  • Vaginitis

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Treatment of complicated Candida vaginitis : Comparison of single and sequential doses of fluconazole. / Sobel, J. D.; Kapernick, P. S.; Zervos, M.; Reed, B. D.; Hooton, Thomas; Soper, D.; Nyirjesy, P.; Heine, M. W.; Willems, J.; Panzer, H.; Wittes, H.

In: American Journal of Obstetrics and Gynecology, Vol. 185, No. 2, 31.08.2001, p. 363-369.

Research output: Contribution to journalArticle

Sobel, JD, Kapernick, PS, Zervos, M, Reed, BD, Hooton, T, Soper, D, Nyirjesy, P, Heine, MW, Willems, J, Panzer, H & Wittes, H 2001, 'Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole', American Journal of Obstetrics and Gynecology, vol. 185, no. 2, pp. 363-369. https://doi.org/10.1067/mob.2001.115116
Sobel, J. D. ; Kapernick, P. S. ; Zervos, M. ; Reed, B. D. ; Hooton, Thomas ; Soper, D. ; Nyirjesy, P. ; Heine, M. W. ; Willems, J. ; Panzer, H. ; Wittes, H. / Treatment of complicated Candida vaginitis : Comparison of single and sequential doses of fluconazole. In: American Journal of Obstetrics and Gynecology. 2001 ; Vol. 185, No. 2. pp. 363-369.
@article{af297b9b617f4e999edc073e76bc547a,
title = "Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole",
abstract = "OBJECTIVE: An attempt was made to validate recent recommendations that women with complicated Candida vaginitis (severe or recurrent, non-albicans Candida spp or abnormal host) require longer-duration antifungal therapy to achieve clinical cure and mycologic eradication. STUDY DESIGN: A prospective, multicenter, randomized, double-blind study was performed comparing a single dose of 150 mg of fluconazole with 2 sequential 150-mg doses of fluconazole given 3 days apart. RESULTS: Five hundred fifty-six women with severe or recurrent Candida vaginitis were enrolled, and 398 had at least one postbaseline evaluation (intent to treat) and of these 309 were fully evaluable (efficacy-valid). At baseline, 92{\%} of vaginal isolates were Candida albicans. The 2-dose fluconazole regimen achieved significantly higher clinical cure rates in women with severe vaginitis when evaluated on day 14 (P = .015) and higher clinical and mycologic responses persisted at day 35. Women with recurrent but not severe vaginitis did not benefit clinically short term by the additional fluconazole dose. Multivariate logistic regression analysis showed that being infected with non-albicans Candida predicted significantly reduced clinical and mycologic response regardless of duration of therapy. Fluconazole therapy was well tolerated and free of serious adverse effects. CONCLUSION: Treatment of Candida vaginitis requires individualization, and women with severe Candida vaginitis achieve superior clinical and mycologic eradication with a 2-dose fluconazole regimen.",
keywords = "Candida, Complicated, Fluconazole, Vaginitis",
author = "Sobel, {J. D.} and Kapernick, {P. S.} and M. Zervos and Reed, {B. D.} and Thomas Hooton and D. Soper and P. Nyirjesy and Heine, {M. W.} and J. Willems and H. Panzer and H. Wittes",
year = "2001",
month = "8",
day = "31",
doi = "10.1067/mob.2001.115116",
language = "English",
volume = "185",
pages = "363--369",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of complicated Candida vaginitis

T2 - Comparison of single and sequential doses of fluconazole

AU - Sobel, J. D.

AU - Kapernick, P. S.

AU - Zervos, M.

AU - Reed, B. D.

AU - Hooton, Thomas

AU - Soper, D.

AU - Nyirjesy, P.

AU - Heine, M. W.

AU - Willems, J.

AU - Panzer, H.

AU - Wittes, H.

PY - 2001/8/31

Y1 - 2001/8/31

N2 - OBJECTIVE: An attempt was made to validate recent recommendations that women with complicated Candida vaginitis (severe or recurrent, non-albicans Candida spp or abnormal host) require longer-duration antifungal therapy to achieve clinical cure and mycologic eradication. STUDY DESIGN: A prospective, multicenter, randomized, double-blind study was performed comparing a single dose of 150 mg of fluconazole with 2 sequential 150-mg doses of fluconazole given 3 days apart. RESULTS: Five hundred fifty-six women with severe or recurrent Candida vaginitis were enrolled, and 398 had at least one postbaseline evaluation (intent to treat) and of these 309 were fully evaluable (efficacy-valid). At baseline, 92% of vaginal isolates were Candida albicans. The 2-dose fluconazole regimen achieved significantly higher clinical cure rates in women with severe vaginitis when evaluated on day 14 (P = .015) and higher clinical and mycologic responses persisted at day 35. Women with recurrent but not severe vaginitis did not benefit clinically short term by the additional fluconazole dose. Multivariate logistic regression analysis showed that being infected with non-albicans Candida predicted significantly reduced clinical and mycologic response regardless of duration of therapy. Fluconazole therapy was well tolerated and free of serious adverse effects. CONCLUSION: Treatment of Candida vaginitis requires individualization, and women with severe Candida vaginitis achieve superior clinical and mycologic eradication with a 2-dose fluconazole regimen.

AB - OBJECTIVE: An attempt was made to validate recent recommendations that women with complicated Candida vaginitis (severe or recurrent, non-albicans Candida spp or abnormal host) require longer-duration antifungal therapy to achieve clinical cure and mycologic eradication. STUDY DESIGN: A prospective, multicenter, randomized, double-blind study was performed comparing a single dose of 150 mg of fluconazole with 2 sequential 150-mg doses of fluconazole given 3 days apart. RESULTS: Five hundred fifty-six women with severe or recurrent Candida vaginitis were enrolled, and 398 had at least one postbaseline evaluation (intent to treat) and of these 309 were fully evaluable (efficacy-valid). At baseline, 92% of vaginal isolates were Candida albicans. The 2-dose fluconazole regimen achieved significantly higher clinical cure rates in women with severe vaginitis when evaluated on day 14 (P = .015) and higher clinical and mycologic responses persisted at day 35. Women with recurrent but not severe vaginitis did not benefit clinically short term by the additional fluconazole dose. Multivariate logistic regression analysis showed that being infected with non-albicans Candida predicted significantly reduced clinical and mycologic response regardless of duration of therapy. Fluconazole therapy was well tolerated and free of serious adverse effects. CONCLUSION: Treatment of Candida vaginitis requires individualization, and women with severe Candida vaginitis achieve superior clinical and mycologic eradication with a 2-dose fluconazole regimen.

KW - Candida

KW - Complicated

KW - Fluconazole

KW - Vaginitis

UR - http://www.scopus.com/inward/record.url?scp=17944363485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944363485&partnerID=8YFLogxK

U2 - 10.1067/mob.2001.115116

DO - 10.1067/mob.2001.115116

M3 - Article

C2 - 11518893

AN - SCOPUS:17944363485

VL - 185

SP - 363

EP - 369

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -